BAXTER INTERNATIONAL INC. (BAX) Spending and interest coverage
- R&D / revenue · 12 months: Value 4.46%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4.46% | Research and development expense / revenue. Period ending 2026-06-30. $512.00M ÷ $11.47B × 100 ≈ 4.46% |
| Stock-based compensation / revenue · 12 months | 1.00% | Share-based compensation / revenue. Period ending 2026-06-30. $115.00M ÷ $11.47B × 100 ≈ 1.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 512.00M USD | Research and Development Expense |
| Revenue | 11.47B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 115.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -274.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $512.00M | $11.47B | $115.00M | $-274.00M | (m) | 4.46% | 1.00% | (m) | (m) |
| 2026-03-31 | $517.00M | $11.32B | $117.00M | $-300.00M | (m) | 4.57% | 1.03% | (m) | (m) |
| 2025-12-31 | $518.00M | $11.24B | $117.00M | $-308.00M | $290.00M | 4.61% | 1.04% | -1.06× | Reported |
| 2025-09-30 | $603.00M | $11.02B | $119.00M | $-14.00M | (m) | 5.47% | 1.08% | (m) | (m) |
| 2025-06-30 | $614.00M | $10.89B | $122.00M | $-31.00M | (m) | 5.64% | 1.12% | (m) | (m) |
| 2025-03-31 | $610.00M | $10.77B | $107.00M | $-43.00M | (m) | 5.66% | 0.99% | (m) | (m) |
| 2024-12-31 | $590.00M | $10.64B | $114.00M | $14.00M | $408.00M | 5.55% | 1.07% | 0.03× | Reported |
| 2024-09-30 | $655.00M | $15.06B | $118.00M | $436.00M | (m) | 4.35% | 0.78% | (m) | (m) |
| 2024-06-30 | $687.00M | $15.00B | $124.00M | $273.00M | $460.00M | 4.58% | 0.83% | 0.59× | Reported |
| 2024-03-31 | $679.00M | $14.89B | $133.00M | $448.00M | $488.00M | 4.56% | 0.89% | 0.92× | Reported |
| 2023-12-31 | $667.00M | $14.81B | $133.00M | $390.00M | $512.00M | 4.50% | 0.90% | 0.76× | Reported |
| 2023-09-30 | $652.00M | $15.28B | $135.00M | $651.00M | $520.00M | 4.27% | 0.88% | 1.25× | Reported |
| 2023-06-30 | $637.00M | $15.18B | $139.00M | $-2.18B | $493.00M | 4.20% | 0.92% | -4.42× | Reported |
| 2023-03-31 | $619.00M | $15.05B | $147.00M | $-1.92B | $454.00M | 4.11% | 0.98% | -4.23× | Reported |
| 2022-12-31 | $605.00M | $15.11B | $154.00M | $-1.94B | $415.00M | 4.00% | 1.02% | -4.68× | Reported |
| 2022-09-30 | $588.00M | $14.74B | $175.00M | $-1.91B | $368.00M | 3.99% | 1.19% | -5.20× | Reported |
| 2022-06-30 | $565.00M | $14.19B | $164.00M | $1.40B | $313.00M | 3.98% | 1.16% | 4.47× | Reported |
| 2022-03-31 | $556.00M | $13.54B | $156.00M | $1.48B | $257.00M | 4.10% | 1.15% | 5.77× | Reported |
| 2021-12-31 | $534.00M | $12.78B | $146.00M | $1.71B | $206.00M | 4.18% | 1.14% | 8.30× | Reported |
| 2021-09-30 | $531.00M | $12.45B | $126.00M | $1.73B | $169.00M | 4.26% | 1.01% | 10.25× | Reported |
| 2021-06-30 | $525.00M | $12.20B | $125.00M | $1.69B | $157.00M | 4.30% | 1.02% | 10.76× | Reported |
| 2021-03-31 | $503.00M | $11.82B | $123.00M | $1.60B | $160.00M | 4.26% | 1.04% | 9.98× | Reported |
| 2020-12-31 | $521.00M | $11.67B | $130.00M | $1.62B | $153.00M | 4.46% | 1.11% | 10.56× | Reported |
| 2020-09-30 | $542.00M | $11.53B | $127.00M | $1.75B | $142.00M | 4.70% | 1.10% | 12.30× | Reported |
| 2020-06-30 | $563.00M | $11.41B | $129.00M | $1.78B | $128.00M | 4.93% | 1.13% | 13.90× | Reported |
| 2020-03-31 | $612.00M | $11.53B | $129.00M | $1.80B | $116.00M | 5.31% | 1.12% | 15.50× | Reported |
| 2019-12-31 | $595.00M | $11.36B | $122.00M | $1.77B | $111.00M | 5.24% | 1.07% | 15.96× | Reported |
| 2019-09-30 | $614.00M | $11.16B | $120.00M | $1.63B | $104.00M | 5.50% | 1.08% | 15.64× | Reported |
| 2019-06-30 | $636.00M | $11.08B | $118.00M | $1.52B | $100.00M | 5.74% | 1.06% | 15.22× | Reported |
| 2019-03-31 | $644.00M | $11.08B | $117.00M | $1.55B | $96.00M | 5.81% | 1.06% | 16.16× | Reported |
| 2018-12-31 | $655.00M | $11.13B | $115.00M | $1.60B | $93.00M | 5.89% | 1.03% | 17.19× | Reported |
| 2018-09-30 | $661.00M | $11.06B | $117.00M | $1.49B | $93.00M | 5.98% | 1.06% | 16.04× | Reported |
| 2018-06-30 | $649.00M | $11.00B | $115.00M | $1.37B | $91.00M | 5.90% | 1.05% | 15.10× | Reported |
| 2018-03-31 | $630.00M | $10.76B | $109.00M | $1.34B | $87.00M | 5.85% | 1.01% | 15.37× | Reported |
| 2017-12-31 | $617.00M | $10.56B | $107.00M | $1.26B | $85.00M | 5.84% | 1.01% | 14.80× | Reported |
| 2017-09-30 | $592.00M | $10.43B | $108.00M | $1.26B | $82.00M | 5.67% | 1.04% | 15.33× | Reported |
| 2017-06-30 | $600.00M | $10.28B | $107.00M | $1.15B | $80.00M | 5.83% | 1.04% | 14.39× | Reported |
| 2017-03-31 | $639.00M | $10.26B | $110.00M | $880.00M | $76.00M | 6.23% | 1.07% | 11.58× | Reported |
| 2016-12-31 | $647.00M | $10.16B | $115.00M | $724.00M | $89.00M | 6.37% | 1.13% | 8.13× | Reported |
| 2016-09-30 | $651.00M | $10.12B | $114.00M | $620.00M | $106.00M | 6.43% | 1.13% | 5.85× | Reported |
| 2016-06-30 | $640.00M | $10.05B | $114.00M | $526.00M | $124.00M | 6.37% | 1.13% | 4.24× | Reported |
| 2016-03-31 | $596.00M | $9.94B | $120.00M | $545.00M | $144.00M | 6.00% | 1.21% | 3.78× | Reported |
| 2015-12-31 | $603.00M | $9.97B | $126.00M | $449.00M | $146.00M | 6.05% | 1.26% | 3.08× | Reported |
| 2015-09-30 | $1.41B | $16.11B | $164.00M | (m) | $145.00M | 8.75% | 1.02% | (m) | Reported |
| 2015-06-30 | $1.48B | $16.33B | $174.00M | (m) | $147.00M | 9.05% | 1.07% | (m) | Reported |
| 2015-03-31 | $1.41B | $16.59B | $167.00M | (m) | $154.00M | 8.51% | 1.01% | (m) | Reported |
| 2014-12-31 | $1.42B | $16.67B | $159.00M | (m) | $167.00M | 8.52% | 0.95% | (m) | Reported |
| 2014-09-30 | $1.56B | $16.81B | $154.00M | (m) | $180.00M | 9.30% | 0.92% | (m) | Reported |
| 2014-06-30 | $1.36B | $16.36B | $150.00M | (m) | $195.00M | 8.35% | 0.92% | (m) | Reported |
| 2014-03-31 | $1.31B | $15.76B | $149.00M | (m) | $172.00M | 8.33% | 0.95% | (m) | Reported |
| 2013-12-31 | $1.25B | $15.26B | $150.00M | (m) | $155.00M | 8.17% | 0.98% | (m) | Reported |
| 2013-09-30 | $1.10B | $14.64B | $144.00M | (m) | $134.00M | 7.51% | 0.98% | (m) | Reported |
| 2013-06-30 | $1.10B | $14.35B | $139.00M | (m) | $114.00M | 7.67% | 0.97% | (m) | Reported |
| 2013-03-31 | $1.13B | $14.25B | $134.00M | (m) | $117.00M | 7.95% | 0.94% | (m) | Reported |
| 2012-12-31 | $1.16B | $14.19B | $130.00M | (m) | $113.00M | 8.15% | 0.92% | (m) | Reported |
| 2012-09-30 | $1.12B | $14.03B | $122.00M | (m) | $110.00M | 7.98% | 0.87% | (m) | Reported |
| 2012-06-30 | $1.07B | $14.03B | $121.00M | (m) | $102.00M | 7.61% | 0.86% | (m) | Reported |
| 2012-03-31 | $1.00B | $14.00B | $119.00M | (m) | $97.00M | 7.15% | 0.85% | (m) | Reported |
| 2011-12-31 | $946.00M | $13.89B | $119.00M | (m) | $92.00M | 6.81% | 0.86% | (m) | Reported |
| 2011-09-30 | $954.00M | $13.80B | $122.00M | (m) | $94.00M | 6.91% | 0.88% | (m) | Reported |
| 2011-06-30 | $922.00M | $13.54B | $118.00M | (m) | $101.00M | 6.81% | 0.87% | (m) | Reported |
| 2011-03-31 | $902.00M | $13.20B | $118.00M | (m) | $109.00M | 6.83% | 0.89% | (m) | Reported |
| 2010-12-31 | $915.00M | $12.84B | $120.00M | (m) | $115.00M | 7.12% | 0.93% | (m) | Reported |
| 2010-09-30 | $899.00M | $12.81B | $126.00M | (m) | (m) | 7.02% | 0.98% | (m) | (m) |
| 2010-06-30 | $920.00M | $12.74B | $129.00M | (m) | (m) | 7.22% | 1.01% | (m) | (m) |
| 2010-03-31 | $932.00M | $12.66B | $132.00M | (m) | (m) | 7.36% | 1.04% | (m) | (m) |
| 2009-12-31 | $917.00M | $12.56B | $140.00M | (m) | (m) | 7.30% | 1.11% | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $868.00M | $12.35B | $146.00M | (m) | (m) | 7.03% | 1.18% | (m) | (m) |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | $760.00M | $11.26B | $136.00M | (m) | (m) | 6.75% | 1.21% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |